Choose Your Country or Region

Anti-Neurofilament Mouse Antibody [E10M6]

Catalog No.: F3838

Application: Reactivity: Human

Usage Information

Dilution
WB1:100 - 1:500 IHC1:200

Application
WB, IHC

Reactivity
Human

Source
Mouse

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
102 kDa 140-160 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human brain cortex tissue; HEK293
Negative Control	A549

Datasheet & SDS

Biological Description

Specificity
Neurofilament Mouse mAb detects endogenous levels of total Neurofilament protein.

Clone
E10M6

Synonym(s)
NEF3, NFM, NEFM, Neurofilament medium polypeptide, NF-M, 160 kDa neurofilament protein, Neurofilament 3, Neurofilament triplet M protein

Background
Neurofilaments are type IV intermediate filaments that play critical roles in maintaining neuronal structure and function. They are composed of four major subunits: neurofilament light (NfL), medium (NfM), heavy (NfH), and the neuronal intermediate filament proteins α-internexin and peripherin. These subunits assemble into heteropolymers that provide mechanical support to axons, regulate axonal diameter, and influence nerve conduction velocity. Neurofilaments participate in synaptic architecture and neurotransmission, showing unique isoform stoichiometry and phosphorylation states at synapses. Neurofilament proteins are tightly regulated through complex mechanisms, including gene expression, post-translational modifications such as phosphorylation, and controlled degradation primarily via proteases like calpain and cathepsin D. Their phosphorylation state particularly affects filament stability, spacing, and interactions with motor proteins essential for axonal transport and vesicle dynamics. Neurofilaments are emerging as robust biomarkers for neurodegenerative and neuroinflammatory diseases due to their release into cerebrospinal fluid and blood following neuronal injury. Elevated levels of neurofilament light chain (NfL) correlate strongly with disease progression in conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease, and Huntington’s disease.

Background

Neurofilaments are type IV intermediate filaments that play critical roles in maintaining neuronal structure and function. They are composed of four major subunits: neurofilament light (NfL), medium (NfM), heavy (NfH), and the neuronal intermediate filament proteins α-internexin and peripherin. These subunits assemble into heteropolymers that provide mechanical support to axons, regulate axonal diameter, and influence nerve conduction velocity. Neurofilaments participate in synaptic architecture and neurotransmission, showing unique isoform stoichiometry and phosphorylation states at synapses. Neurofilament proteins are tightly regulated through complex mechanisms, including gene expression, post-translational modifications such as phosphorylation, and controlled degradation primarily via proteases like calpain and cathepsin D. Their phosphorylation state particularly affects filament stability, spacing, and interactions with motor proteins essential for axonal transport and vesicle dynamics. Neurofilaments are emerging as robust biomarkers for neurodegenerative and neuroinflammatory diseases due to their release into cerebrospinal fluid and blood following neuronal injury. Elevated levels of neurofilament light chain (NfL) correlate strongly with disease progression in conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease, and Huntington’s disease.

References
https://pubmed.ncbi.nlm.nih.gov/22956720/ https://pubmed.ncbi.nlm.nih.gov/32408345/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%